LUCID PSYCHECEUTICALS INC.
Therapeutic solutions for Total Brain Health
At Lucid Psycheceuticals Inc., we’re passionate about developing therapeutics inspired by psychadelics and novel small molecule drugs. We think outside the box and patient-oriented therapeutic solutions in mental health and neurodegenerative disorders. We are developing therapeutics for the mind and brain health, which are intertwined. Our founding team and the scientific prowess, our commitment to patient needs remains the key driving force behind our company. Get in touch today to learn more.
News: Lucid founder and CEO, Dr. Lakshmi Kotra was awarded the 2020 The Julia Levy Award by the Society of Chemical Industry (SCI) Canada. A humbling recognition...
Brain is the ultimate frontier in health research. Depression, anxiety, dementia and similar conditions often are prodromes to more serious neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis etc. Inspired by the mechanisms of action of psychadelics, and the need for therapeutics to prevent, possibly reverse, neurodegeneration, Lucid is exploring novel therapies to address total brain health, i.e. mind and biology behind it!
Lucid is bringing together all possible tools to validate solutions at the bench to transition into clinical studies. Lucid scientists understand the value and the role of various tools such as artificial intelligence, chemical libraries, in vitro screening solutions, various animal models, pragmatic therapeutic strategies, regulatory approaches and clinical trials. With a bold thinking to prevent and reverse, if possible, neurodegeneration and address prodromal conditions, Lucid has preclinical assets under development.
Lucid R&D is conducted through leading drug research laboratories at University Health Network, Canada’s largest research hospital, and various partner companies.
Lucid has been silently conducting its R&D with no announcements, and laser focused on its mission. Stay tuned for more...